299411-67-9

Usage

Uses

Used in Research and Development:
Ethanone, 2-chloro-1-(4-chloro-2-fluorophenyl)(9CI) is used as a research compound for studying its chemical properties and potential applications.
Used in Pharmaceutical Production:
Ethanone, 2-chloro-1-(4-chloro-2-fluorophenyl)(9CI) is used as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs.
Used in Agrochemical Production:
Ethanone, 2-chloro-1-(4-chloro-2-fluorophenyl)(9CI) is used as a building block in the production of agrochemicals, aiding in the creation of effective pesticides and other agricultural products.
Used in Organic Synthesis:
Ethanone, 2-chloro-1-(4-chloro-2-fluorophenyl)(9CI) is used as a reactant in various organic synthesis processes, enabling the formation of complex organic molecules.
Note: The specific applications and industries for Ethanone, 2-chloro-1-(4-chloro-2-fluorophenyl)(9CI) are not explicitly mentioned in the provided materials. The uses listed above are inferred based on the general applications of similar chemical compounds. Further research is needed to fully understand its potential benefits and risks.

Upstream product

• 175711-83-8 4’-chloro-2’-fluoroacetophenone 

Downstream Products

• 1229236-81-0 2-((6-chloro-3-(4-chloro-2-fluorobenzoyl)-2-methylimidazo[1,2-b]pyridazin-8-yl)methyl)isoindoline-1,3-dione 
• 1229236-83-2 (4-chloro-2-fluorophenyl)(6-chloro-2-methyl-8-(morpholino-methyl)imidazo[1,2-b]pyridazin-3-yl)methanone 
• 1346221-91-7 N-(1-tert-butyl-3-methyl-1H-pyrazol-5-yl)-3-(4-chloro-2-fluorobenzyl)-2-methyl-8-(morpholinomethyl)imidazo[1,2-b]pyridazin-6-amine 
• 1000201-64-8 (Z)-4-chloro-1-[3-chloro-1-(2-chlorophenyl)prop-1-en-2-yl]-2-fluoro-benzene 

Relevant academic research and scientific papers

IMIDAZO[1,2-B]PYRIDAZIN-6-AMINE DERIVATIVES AS KINASE JAK-2 INHIBITORS

A compound represented by the general formula (I) wherein R1represents H or C1-C4 alkyl; R2 represents phenyl substituted with one or two substituents selected from the group consisting of halogen atom and OCsu

Aminoazabenzimidazoles, a Novel Class of Orally Active Antimalarial Agents

Whole-cell high-throughput screening of the AstraZeneca compound library against the asexual blood stage of Plasmodium falciparum (Pf) led to the identification of amino imidazoles, a robust starting point for initiating a hit-to-lead medicinal chemistry effort. Structure-activity relationship studies followed by pharmacokinetics optimization resulted in the identification of 23 as an attractive lead with good oral bioavailability. Compound 23 was found to be efficacious (ED90 of 28.6 mg·kg-1) in the humanized P. falciparum mouse model of malaria (Pf/SCID model). Representative compounds displayed a moderate to fast killing profile that is comparable to that of chloroquine. This series demonstrates no cross-resistance against a panel of Pf strains with mutations to known antimalarial drugs, thereby suggesting a novel mechanism of action for this chemical class.

Development and a practical synthesis of the JAK2 inhibitor LY2784544

The route selection and process research and development of a practical synthesis for JAK2 inhibitor LY2784544 is described. The first-generation synthesis route, similar to that used in discovery for derivatization of a benzylic amine moiety, was 14 overall steps and possessed several steps that required extensive development for large-scale production. Route selection considerations led to a modified synthesis that utilized a novel vanadium-catalyzed carbon-carbon bond-forming arylation reaction for incorporation of the key benzylic morpholine moiety. A protecting group used to mask an amino pyrazole unit was modified from PMB to tert-butyl, resulting in a dramatic reduction in the overall length of the route. These two major changes resulted in an eight-step synthesis, which was six steps shorter than the first-generation synthesis. In the pilot plant, the new synthesis was scaled to produce >100 kg of LY2784544 in high yield and purity under GMP conditions. The overall development including the vanadium-catalyzed C-C bond-forming methodology, a ketone reductive deoxygenation, and a palladium-catalyzed amination is described.

AMINO PYRAZOLE COMPOUND

The present invention provides amino pyrazole compounds useful in the treatment of chronic myeloproliferative disorders and various cancers, e.g., glioblastoma, breast cancer, multiple myeloma, prostate cancer, and leukemias.